1. Home
  2. ATEN vs OCS Comparison

ATEN vs OCS Comparison

Compare ATEN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$23.88

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

HOLD

Current Price

$26.42

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEN
OCS
Founded
2004
2003
Country
United States
Switzerland
Employees
N/A
3
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ATEN
OCS
Price
$23.88
$26.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$24.00
$42.00
AVG Volume (30 Days)
800.9K
332.0K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
$235,429,000.00
N/A
Revenue This Year
$13.02
$466.06
Revenue Next Year
$10.39
$479.73
P/E Ratio
$42.07
N/A
Revenue Growth
2.36
N/A
52 Week Low
$13.81
$14.00
52 Week High
$24.22
$30.68

Technical Indicators

Market Signals
Indicator
ATEN
OCS
Relative Strength Index (RSI) 71.22 52.18
Support Level $17.12 $25.99
Resistance Level N/A $29.19
Average True Range (ATR) 0.71 1.22
MACD 0.14 0.16
Stochastic Oscillator 93.78 66.75

Price Performance

Historical Comparison
ATEN
OCS

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Share on Social Networks: